<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790659</url>
  </required_header>
  <id_info>
    <org_study_id>S-12-21</org_study_id>
    <nct_id>NCT01790659</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama</brief_title>
  <official_title>A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a pivotal Phase 3, randomized, double-blind, 3-site, two-group trial assessing
      the efficacy and safety of WR 279,396 Topical Cream and Paromomycin Alone Topical Cream in
      subjects with CL in Panama. The primary objective of this study is to determine if WR 279,396
      results in statistically superior final clinical cure rates of an index lesion when compared
      with Paromomycin Alone for the treatment of CL in Panama expected to be caused by L
      panamensis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be recruited from three regions in Panama known to be endemic for L panamensis
      CL. Subjects will be screened over a period up to 28 days for eligibility including medical
      history, physical examination, leishmaniasis history, vital signs, clinical chemistry, prior
      medications, and parasitology for confirmation of ulcerative CL. If eligible, subjects will
      be randomized in a targeted 1:1 ratio (200 subjects per group) using site as a stratification
      variable to receive either WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) or
      Paromomycin Alone (15% paromomycin topical cream) by topical application to CL lesions once
      daily for 20 days. Efficacy will be assessed by measuring the size of the index lesion ulcer,
      non-index lesions ulcers, and overall size of other non-ulcerated lesions at baseline (before
      the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ±
      14 days, and 168 ± 14 days. A notation will be made if clinical evidence of parasite
      persistence is observed at the Day 63 and beyond visits including significant erythema and
      induration when a lesion has otherwise completely re-epithelialized to document any subjects
      removed from the study early if the investigator judges them to be in need of rescue
      treatment. A photograph will be taken of all lesions at baseline, Day 20 and each of the
      follow-up visits. Safety will be assessed by monitoring adverse events (AEs) from the start
      of treatment until study completion, lesion site reactions during treatment, physical
      examination of the nasal and oral mucosa for appearance of mucosal leishmaniasis on Days 63 ±
      7 days, 100 ± 14 days, and 168 ± 14 days, concomitant medication use for the duration of the
      study, blood creatinine, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
      levels on Study Day 20. After the sponsor's approval, biochemistry can be repeated in the
      case of abnormal results and if the causes of these results could not be determined. A repeat
      pregnancy test on Day 35. Recent infection with leishmaniasis prior to the start of the study
      may result in the development of lesions that were not present at the start of the study that
      did not receive treatment. New lesions may be treated at the discretion of the investigator
      with the topical cream to which the subject was assigned any time during the conduct of the
      study except that treatment must be completed by the Day 168 visit. If a new lesion is
      discovered at the final study visit, the subject will be referred to their primary physician
      for treatment.

      Subjects who fail therapy (see definition of failure below) will be taken off study and may
      be administered rescue therapy at the discretion of the subject's personal physician. If the
      subject met the criteria for therapy failure but was undergoing treatment for new lesions,
      the subject can continue in the study (by signing a consent addendum) if the investigator
      decides it is in the best interest of the subject to do so.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Final Clinical Cure</measure>
    <time_frame>baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days</time_frame>
    <description>The primary efficacy endpoint is percent of subjects with final clinical cure. Final clinical cure is defined as follows:
Subject has initial clinical cure (100% re-epithelialization of index lesion by nominal Day 63); OR,
Subject has initial clinical improvement (&gt; 50% re-epithelialization of index lesion by nominal Day 63) followed by 100% re-epithelialization of the index lesion on or before nominal Day 100; AND,
Subject has no relapse of index lesion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With All Lesions Cured</measure>
    <time_frame>100 ± 14 days</time_frame>
    <description>• Percentage of subjects with all lesions cured, defined as: Final clinical cure as defined in primary objective (which is based solely on the index lesion); AND, Cure of all other lesions by nominal Day 100 (100% re-epithelialization of all ulcerated lesions and resolution of all other types of lesions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of All Lesions Cured at Day 168 (Ignores Per Subject Cure Rate)</measure>
    <time_frame>Day 168</time_frame>
    <description>Percentage of all lesions meeting criteria for clinical cure during the study at 168 day mark for mITT subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of Ulceration (mm^2) of the Index Lesion at Each Measurement Time Point</measure>
    <time_frame>baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days</time_frame>
    <description>Area of ulceration (mm^2) of the index lesion at each measurement time point for mITT subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of Ulceration (mm^2) All Treated Lesions at Each Measurement Time Point</measure>
    <time_frame>baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days</time_frame>
    <description>Area of ulceration (mm^2) of all treated lesions from baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days for mITT subjects. Data presented is as presented in the Final Clinical Study Report; any inconsistencies can't be changed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Initial Clinical Cure for Index Lesions</measure>
    <time_frame>When 100% re-epithelialization of the index lesion is observed at any visit Study Days (20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days</time_frame>
    <description>Median time to initial clinical cure for index lesions (100% re-epithelialization of the index lesion)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">399</enrollment>
  <condition>Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>WR 279,396</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Paromomycin and Gentamicin Topical Cream)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paromomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paromomycin alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WR 279,396</intervention_name>
    <description>WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%</description>
    <arm_group_label>WR 279,396</arm_group_label>
    <other_name>Paromomycin/Gentamicin topical cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paromomycin</intervention_name>
    <description>Paromomycin alone</description>
    <arm_group_label>Paromomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 2 years-of-age

          -  Subject or legal guardian able to give written informed consent or assent, as
             appropriate

          -  Diagnosis of CL in at least one lesion by at least one of the following methods: 1)
             positive culture for promastigotes or 2) microscopic identification of amastigotes in
             stained lesion tissue

          -  At least one ulcerative lesion ≥ 1 cm and ≤ 5 cm that has a diagnosis of CL

          -  Willing to forego other forms of treatments for CL including other investigational
             treatments during the study

          -  In the opinion of the investigator, subject (or their legal guardian), subject is
             capable of understanding and complying with the protocol

          -  If female and of child-bearing potential, must have a negative serum pregnancy test
             during screening and agree to use an acceptable method of birth control during the
             treatment phase and for 1 week after treatment is completed

        Exclusion Criteria:

          -  Lesion due to leishmania that involves the nasal or oral mucosa or any signs of
             mucosal disease that might be due to Leishmania

          -  Only a single lesion on the ear with erosive cartilage

          -  Signs and symptoms of disseminated disease in the opinion of the investigator

          -  More than 10 lesions

          -  Female who is breast-feeding

          -  Significant organ abnormality, chronic disease such as diabetes, severe hearing loss,
             evidence of renal or hepatic dysfunction, or creatinine, aspartate aminotransferase
             (AST), or alanine aminotransferase (ALT) greater than 15% above the upper limit of
             normal (ULN) as defined by the clinical laboratory defined normal ranges

          -  Received treatment for leishmaniasis including any medication with pentavalent
             antimony including sodium stibogluconate (Pentostam™), meglumine antimoniate
             (Glucantime™); amphotericin B (including liposomal amphotericin B and amphotericin B
             deoxycholate); or other medications containing paromomycin (administered parenterally
             or topically) or methylbenzethonium chloride (MBCL); gentamicin; fluconazole;
             ketoconazole; pentamidine; miltefosine, azithromycin or allopurinol that was completed
             within 56 days of starting study treatments

          -  History of known or suspected hypersensitivity or idiosyncratic reactions to
             aminoglycosides
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nestor Sosa, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Conmemorativo Gorgas de Estudios de la Salud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Conmemorativo Gorgas de Estudios de la Salud,</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <results_first_submitted>October 11, 2016</results_first_submitted>
  <results_first_submitted_qc>July 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2017</results_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leishmaniasis</keyword>
  <keyword>cutaneous leishmaniasis</keyword>
  <keyword>Leishmania panamensis</keyword>
  <keyword>L panamensis</keyword>
  <keyword>Paromomycin</keyword>
  <keyword>Paromomycin/Gentamicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Paromomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from three regions in Panama. Subjects were screened over a 28 day period.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>WR 279,396</title>
          <description>(Paromomycin and Gentamicin Topical Cream)
WR 279,396: WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%</description>
        </group>
        <group group_id="P2">
          <title>Paromomycin</title>
          <description>Paromomycin alone
Paromomycin: Paromomycin alone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="192"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>WR 279,396</title>
          <description>(Paromomycin and Gentamicin Topical Cream)
WR 279,396: WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%</description>
        </group>
        <group group_id="B2">
          <title>Paromomycin</title>
          <description>Paromomycin alone
Paromomycin: Paromomycin alone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="201"/>
            <count group_id="B2" value="198"/>
            <count group_id="B3" value="399"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.9" spread="16.8"/>
                    <measurement group_id="B2" value="23.6" spread="15.1"/>
                    <measurement group_id="B3" value="23.2" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="397"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="390"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of baseline lesions</title>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.27" spread="1.71"/>
                    <measurement group_id="B2" value="2.13" spread="1.63"/>
                    <measurement group_id="B3" value="2.20" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion sizes</title>
          <description>Lesion size was calculated in mm</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120" spread="146"/>
                    <measurement group_id="B2" value="121" spread="152"/>
                    <measurement group_id="B3" value="120" spread="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Length of time between initial presence current lesions and treatment</title>
          <description>Length of time in days before treatment that lesions were first noticed</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="53.6"/>
                    <measurement group_id="B2" value="62.1" spread="57.7"/>
                    <measurement group_id="B3" value="60.9" spread="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Final Clinical Cure</title>
        <description>The primary efficacy endpoint is percent of subjects with final clinical cure. Final clinical cure is defined as follows:
Subject has initial clinical cure (100% re-epithelialization of index lesion by nominal Day 63); OR,
Subject has initial clinical improvement (&gt; 50% re-epithelialization of index lesion by nominal Day 63) followed by 100% re-epithelialization of the index lesion on or before nominal Day 100; AND,
Subject has no relapse of index lesion.</description>
        <time_frame>baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days</time_frame>
        <population>MITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>WR 279,396</title>
            <description>(Paromomycin and Gentamicin Topical Cream)
WR 279,396: WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Paromomycin</title>
            <description>Paromomycin alone
Paromomycin: Paromomycin alone</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Final Clinical Cure</title>
          <description>The primary efficacy endpoint is percent of subjects with final clinical cure. Final clinical cure is defined as follows:
Subject has initial clinical cure (100% re-epithelialization of index lesion by nominal Day 63); OR,
Subject has initial clinical improvement (&gt; 50% re-epithelialization of index lesion by nominal Day 63) followed by 100% re-epithelialization of the index lesion on or before nominal Day 100; AND,
Subject has no relapse of index lesion.</description>
          <population>MITT subjects</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With All Lesions Cured</title>
        <description>• Percentage of subjects with all lesions cured, defined as: Final clinical cure as defined in primary objective (which is based solely on the index lesion); AND, Cure of all other lesions by nominal Day 100 (100% re-epithelialization of all ulcerated lesions and resolution of all other types of lesions)</description>
        <time_frame>100 ± 14 days</time_frame>
        <population>MITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>WR 279,396</title>
            <description>(Paromomycin and Gentamicin Topical Cream)
WR 279,396: WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Paromomycin</title>
            <description>Paromomycin alone
Paromomycin: Paromomycin alone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With All Lesions Cured</title>
          <description>• Percentage of subjects with all lesions cured, defined as: Final clinical cure as defined in primary objective (which is based solely on the index lesion); AND, Cure of all other lesions by nominal Day 100 (100% re-epithelialization of all ulcerated lesions and resolution of all other types of lesions)</description>
          <population>MITT subjects</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1"/>
                    <measurement group_id="O2" value="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of All Lesions Cured at Day 168 (Ignores Per Subject Cure Rate)</title>
        <description>Percentage of all lesions meeting criteria for clinical cure during the study at 168 day mark for mITT subjects</description>
        <time_frame>Day 168</time_frame>
        <population>Cure rates of all lesions over time without regard to subject for mITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>WR 279,396</title>
            <description>(Paromomycin and Gentamicin Topical Cream)
WR 279,396: WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Paromomycin</title>
            <description>Paromomycin alone
Paromomycin: Paromomycin alone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of All Lesions Cured at Day 168 (Ignores Per Subject Cure Rate)</title>
          <description>Percentage of all lesions meeting criteria for clinical cure during the study at 168 day mark for mITT subjects</description>
          <population>Cure rates of all lesions over time without regard to subject for mITT subjects</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area of Ulceration (mm^2) of the Index Lesion at Each Measurement Time Point</title>
        <description>Area of ulceration (mm^2) of the index lesion at each measurement time point for mITT subjects</description>
        <time_frame>baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days</time_frame>
        <population>mITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>WR 279,396</title>
            <description>(Paromomycin and Gentamicin Topical Cream)
WR 279,396: WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Paromomycin</title>
            <description>Paromomycin alone
Paromomycin: Paromomycin alone</description>
          </group>
        </group_list>
        <measure>
          <title>Area of Ulceration (mm^2) of the Index Lesion at Each Measurement Time Point</title>
          <description>Area of ulceration (mm^2) of the index lesion at each measurement time point for mITT subjects</description>
          <population>mITT subjects</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153" spread="137"/>
                    <measurement group_id="O2" value="165" spread="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="831" spread="627"/>
                    <measurement group_id="O2" value="928" spread="986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="677" spread="602"/>
                    <measurement group_id="O2" value="762" spread="933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3" spread="138"/>
                    <measurement group_id="O2" value="96.1" spread="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-84.1" spread="156"/>
                    <measurement group_id="O2" value="-69.9" spread="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="87.2"/>
                    <measurement group_id="O2" value="33.9" spread="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Day 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-123" spread="144"/>
                    <measurement group_id="O2" value="-132" spread="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="119"/>
                    <measurement group_id="O2" value="27.6" spread="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Day 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-123" spread="167"/>
                    <measurement group_id="O2" value="-136" spread="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="85.9"/>
                    <measurement group_id="O2" value="7.41" spread="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-144" spread="163"/>
                    <measurement group_id="O2" value="-152" spread="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="111"/>
                    <measurement group_id="O2" value="1.37" spread="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-147" spread="171"/>
                    <measurement group_id="O2" value="-160" spread="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area of Ulceration (mm^2) All Treated Lesions at Each Measurement Time Point</title>
        <description>Area of ulceration (mm^2) of all treated lesions from baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days for mITT subjects. Data presented is as presented in the Final Clinical Study Report; any inconsistencies can't be changed.</description>
        <time_frame>baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days</time_frame>
        <population>All lesions for mITT Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>WR 279,396</title>
            <description>(Paromomycin and Gentamicin Topical Cream)
WR 279,396: WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Paromomycin</title>
            <description>Paromomycin alone
Paromomycin: Paromomycin alone</description>
          </group>
        </group_list>
        <measure>
          <title>Area of Ulceration (mm^2) All Treated Lesions at Each Measurement Time Point</title>
          <description>Area of ulceration (mm^2) of all treated lesions from baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days for mITT subjects. Data presented is as presented in the Final Clinical Study Report; any inconsistencies can't be changed.</description>
          <population>All lesions for mITT Subjects</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Number of lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="457"/>
                <count group_id="O2" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" spread="152"/>
                    <measurement group_id="O2" value="115" spread="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="656" spread="683"/>
                    <measurement group_id="O2" value="699" spread="897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533" spread="632"/>
                    <measurement group_id="O2" value="577" spread="829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0" spread="132"/>
                    <measurement group_id="O2" value="66.1" spread="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.8" spread="167"/>
                    <measurement group_id="O2" value="-51.9" spread="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="76.8"/>
                    <measurement group_id="O2" value="23.9" spread="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Day 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-93.8" spread="160"/>
                    <measurement group_id="O2" value="-92.1" spread="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="94.6"/>
                    <measurement group_id="O2" value="15.8" spread="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Day 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-96.2" spread="170"/>
                    <measurement group_id="O2" value="-98.7" spread="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.49" spread="58.8"/>
                    <measurement group_id="O2" value="4.64" spread="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-113" spread="166"/>
                    <measurement group_id="O2" value="-109" spread="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.14" spread="87.7"/>
                    <measurement group_id="O2" value="0.83" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-118" spread="182"/>
                    <measurement group_id="O2" value="-114" spread="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Initial Clinical Cure for Index Lesions</title>
        <description>Median time to initial clinical cure for index lesions (100% re-epithelialization of the index lesion)</description>
        <time_frame>When 100% re-epithelialization of the index lesion is observed at any visit Study Days (20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days</time_frame>
        <population>MITT subjects</population>
        <group_list>
          <group group_id="O1">
            <title>WR 279,396</title>
            <description>(Paromomycin and Gentamicin Topical Cream)
WR 279,396: WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Paromomycin</title>
            <description>Paromomycin alone
Paromomycin: Paromomycin alone</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Initial Clinical Cure for Index Lesions</title>
          <description>Median time to initial clinical cure for index lesions (100% re-epithelialization of the index lesion)</description>
          <population>MITT subjects</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.000" lower_limit="35" upper_limit="49"/>
                    <measurement group_id="O2" value="48.000" lower_limit="36" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE's were assessed at baseline, days 2-9 daily, day 20, 35, 49, 63, 100, and 168 (applicable)</time_frame>
      <desc>AE's including application site reactions including elicited examination for pain, and clinician examination for erythema/redness, swelling/edema and vesicles. Physical examination findings of evidence of mucosal leishmaniasis will be reported as an AE.</desc>
      <group_list>
        <group group_id="E1">
          <title>WR 279,396</title>
          <description>(Paromomycin and Gentamicin Topical Cream)
WR 279,396: WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%</description>
        </group>
        <group group_id="E2">
          <title>Paromomycin</title>
          <description>Paromomycin alone
Paromomycin: Paromomycin alone</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection of surgical site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Second degree burn: scalding water</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Appendectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Appendectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="198" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Lymphadenitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Lymphadenopathy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain (upper)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dermatitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="201"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Application site erosion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Application site injury</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="201"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="201"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Mucosal erosion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cutaneous Leishmaniasis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="201"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="201"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="201"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="201"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Mucocutaneous Leishmaniasis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="126" subjects_affected="126" subjects_at_risk="201"/>
                <counts group_id="E2" events="112" subjects_affected="112" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="201"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="201"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Superinfection bacterial</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="201"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthrpod bite</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="201"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="201"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="99" subjects_affected="99" subjects_at_risk="201"/>
                <counts group_id="E2" events="97" subjects_affected="97" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Pruritus</sub_title>
                <counts group_id="E1" events="60" subjects_affected="60" subjects_at_risk="201"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="201"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nestor Sosa, MD, FACP</name_or_title>
      <organization>Instituto Conmemorativo Gorgas de Estudios de la Salud</organization>
      <phone>507-527-4950</phone>
      <email>drnsosa@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

